KR20220033777A - Composition for improving, relieving or preventing andropause symptoms and functional food comprising the same - Google Patents

Abstract

Provided are a composition for alleviating, relieving, or preventing andropause syndrome, comprising an extract of fermented Momordica charantia (bitter melon) as an active ingredient, and a functional food containing the same.

Description

Composition for improving, alleviating or preventing male menopausal syndrome, and functional food containing the same

The present invention relates to a composition for improving, alleviating or preventing male menopausal syndrome and a functional food containing the same. More particularly, the present invention relates to a composition for improving, alleviating or preventing androgenic syndrome by ameliorating testosterone deficiency or deficiency, and a functional food comprising the same.

Male menopause (PADAM; Partial Androgen Deficiency in Aging Male) is a process in which men experience overall physical and mental decline according to the aging of the body. Male menopause refers to a gradual decline in masculine characteristics, overall life vitality, or mood due to the effect of a decrease in male hormones. Symptoms of male menopause include irritability, emotional anxiety, depression, dizziness, hot flashes, sweating, sleep disturbance, decreased vitality, memory loss, decreased work capacity, decreased libido, skin aging, decreased bone density, and increased visceral fat. .

Male hormone (androgen) drug replacement therapy is a treatment method for andropause complex syndrome. However, such drug supplementation therapy may exhibit liver toxicity, and side effects such as increasing LDL by affecting blood lipid metabolism and reducing HDL to cause cardiovascular disease are problematic. In addition, the administration of male hormones may have adverse effects on liver, lipid status, cardiovascular and prostate diseases, and sleep and behavioral disorders, and there is a problem that requires regular examination for these side effects. On the one hand, it has been reported that androgen therapy cannot be provided in the presence of asymptomatic or overt prostate cancer.

Recently, in order to overcome the problems caused by the treatment regimen of these drugs, development of an andropause complex syndrome improving agent containing natural herbal medicines as a main component has been attempted. For example, there is a pharmaceutical composition for improving sexual function comprising an extract of sumac tree. However, the prior art with such herbal ingredients as the main ingredient is mainly limited to research related to sexual function, which is a fragmentary symptom of androgenic complex syndrome. As a result, the development of drugs for improving andropause complex syndrome is insufficient.

In addition, some techniques disclose a mixture of a number of herbal medicines that are effective for male virility and nourishment, and the function of specific ingredients is not clearly revealed. Herbal medicines have a characteristic that their use for diseases is completely different depending on the complex ingredients and usage because they have a mutual effect when several types of herbal ingredients are mixed and used. In addition, the available herbal medicines are all different depending on the constitution of the person or the disease they already have, so it is difficult to actually apply it to the patient as it is by simply compounding the materials with similar efficacy. As such, the development of herbal medicines applicable to the improvement of symptoms of male menopause is still in a rudimentary stage.

Background art of the present invention is disclosed in Korean Patent No. 10-2122408 and the like.

It is an object of the present invention to provide a composition and a functional food that provide the effect of treating, ameliorating, alleviating or preventing male menopausal syndrome.

One aspect of the present invention is a food composition for the improvement, alleviation or prevention of male menopausal syndrome.

A food composition for alleviating, alleviating or preventing androgenic syndrome contains an extract of fermented bitter melon ( Momordica charantia ) as an active ingredient.

Another aspect of the present invention is a pharmaceutical composition for the treatment, improvement, alleviation or prevention of andropause syndrome.

A pharmaceutical composition for treating, alleviating, alleviating or preventing male menopausal syndrome contains an extract of fermented bitter gourd as an active ingredient.

Another aspect of the present invention is a functional food for the improvement, alleviation or prevention of male menopausal syndrome.

The functional food for improving, alleviating, or preventing androgenic syndrome contains the food composition for alleviating, alleviating or preventing androgenic syndrome of the present invention.

The present invention provides a composition and a functional food that provide the effect of treating, ameliorating, alleviating or preventing male menopausal syndrome.

1 is an analysis result of total testosterone content, SHBG content, free testosterone content, and prostate-specific antigen (PSA) content.
2 is an analysis result of body weight, abdominal fat, vastus lateral muscle, and various lipid contents.
3 is a result of analysis of the number of forced swimming test, total sperm, and motile sperm.
4 is a result of analysis of the expression of testosterone biosynthesis-related genes.
5 is a liver toxicity test result by ALT and AST analysis.
1 to 5, "C" refers to a group to which neither the extract of Example 1 nor the extract of Comparative Example 1 was administered.

In the present specification, "X to Y" when referring to a numerical range means "X or more and Y or less (X≤ and ≤Y)".

The present inventors ferment bitter melon ( Momordica charantia , bitter melon) with Lactobacillus plantarum among the genus Lactobacillus and then solvent extraction. The present invention was completed by confirming that the

Hereinafter, a composition according to an embodiment of the present invention will be described in detail.

The composition of the present invention contains an extract of fermented bitter gourd.

The extract of fermented bitter melon can significantly improve the total testosterone content and the free testosterone content. In addition, the extract of fermented bitter gourd increased the expression of 17, 20-lyase and 17β-HSD3, which are enzymes involved in testosterone biosynthesis, while aromatase and 5α-lyase, which are enzymes related to the degradation of testosterone, were increased. Reducing the expression of reductase can increase and restore free testosterone levels in the body. In addition, fermented bitter melon extract can increase muscle mass, forced swimming time, total and motile sperm count, while lowering sex hormone binding globulin, abdominal fat, total cholesterol and triglyceride content in plasma. there is. In this way, the extract of fermented bitter gourd can provide the effect of ameliorating, preventing or alleviating the androgenic syndrome associated with testosterone deficiency or deficiency.

The composition of the present invention reduces testosterone, decreases muscle mass, decreases sperm count, decreases motility sperm, decreases expression of enzymes related to testosterone biosynthesis, increases expression of enzymes related to decomposition of testosterone. Or it may be a food composition that provides an alleviating effect.

The food composition may be used in the form of candy, syrup, beverage, pill, tablet, capsule, powder, powder, granule, etc., but is not particularly limited thereto.

The composition of the present invention reduces testosterone, decreases muscle mass, decreases sperm count, decreases motility sperm, decreases expression of enzymes related to testosterone biosynthesis, increases expression of enzymes related to testosterone degradation, treatment, improvement of androgenic syndromes , it may be a pharmaceutical composition that provides a preventive or alleviating effect.

The pharmaceutical composition may be used in the form of granules, pills, tablets, and the like.

The pharmaceutical composition may further include a pharmaceutically acceptable carrier, excipient or diluent. The pharmaceutical composition of the present invention may be administered orally or parenterally, and when administered parenterally, it is preferable to select an external skin or intraperitoneal, rectal, intravenous, muscle, subcutaneous, intrauterine dural or intracerebrovascular injection method.

The pharmaceutical composition may be formulated using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include one or more compounds and at least one excipient, for example, starch, calcium carbonate, sucrose or lactose ( lactose), gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. there is. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent and the suspending solvent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As the base of the suppository, witepsol, macrogol, Tween 61, cacao butter, laurin fat, glycero gelatin, etc. can be used.

The pharmaceutical composition is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type, severity, and drug activity of the patient. , can be determined according to factors including sensitivity to drug, administration time, administration route and excretion rate, duration of treatment, concurrent drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. In consideration of all of the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by a person skilled in the art.

The dosage of the pharmaceutical composition can be used in various ranges depending on the weight, age, sex, health status, diet, administration time, administration method, excretion rate and severity of the disease of the patient.

The extract of fermented bitter gourd is contained as an active ingredient in the composition. In one embodiment, the extract of the fermented bitter gourd may be included in an amount of 0.001 wt% to 10 wt%, specifically 0.01 wt% to 5 wt%, based on the solid content of the composition. Within the above range, it is possible to provide the effect of improving testosterone deficiency or deficiency-related male menopausal syndrome of the present invention.

The fermented bitter gourd extract can be prepared by adding water to pulverized dried bitter gourd or raw bitter gourd, adding Lactobacillus plantarum among Lactobacillus genus, followed by fermentation, and hot water extraction or ethanol extraction of the obtained fermented product. The present invention is characterized in that the extract of fermented bitter gourd is prepared by first adding Lactobacillus plantarum to dry bitter gourd or raw bitter melon to ferment, and then extracting the obtained fermented product with hot water or ethanol.

Among the genus Lactobacillus, Lactobacillus plantarum can enable the fermented bitter melon extract of the present invention to effectively implement the effect related to the improvement, prevention or alleviation of the syndrome associated with testosterone deficiency or deficiency of the present invention.

Fermentation may be carried out under normal fermentation conditions after adding water to dry bitter gourd or raw bitter melon and adding Lactobacillus plantarum. For example, fermentation may be performed at 30° C. to 40° C. for 50 hours to 100 hours. Within the above range, it may be easy to prepare an extract of fermented bitter gourd that provides the effects of the present invention.

By hot water extraction or ethanol extraction of the obtained fermented product, the extract of the fermented bitter gourd of the present invention can be prepared. Hot water extraction may be performed while heating the obtained fermented product in hot water at 70° C. to 85° C. The hot water extraction time is not particularly limited, but may be, for example, 10 to 30 hours. Within the above range, it may be easy to prepare an extract of fermented bitter gourd that provides the effects of the present invention.

The inoculated Lactobacillus plantarum remains active in the extract of fermented bitter gourd, and in order to use it for drinking purposes, it is necessary to suppress the activity of Lactobacillus plantarum. Although it is possible to inhibit the activity of lantarum, the step of inhibiting the activity of Lactobacillus plantarum contained in the separately fermented bitter gourd extraction may be further included in the case of extraction using a low concentration of ethanol.

Meanwhile, the fermented bitter melon extract may be concentrated and/or dried to prolong the storage period of the fermented bitter melon extract or to facilitate processing.

Hereinafter, a functional food according to an embodiment of the present invention will be described.

The functional food includes the fermented bitter melon extract of the present invention or the composition of the present invention.

The functional food may be used in the form of candy, syrup, beverage, pill, tablet, capsule, powder, powder, granule, etc., but is not limited thereto.

Hereinafter, the configuration and operation of the present invention will be described in more detail through preferred embodiments of the present invention. However, this is presented as a preferred example of the present invention and cannot be construed as limiting the present invention in any sense.

Example 1

Approximately 1 x 10 ⁹ pieces of Lactobacillus plantarum (KCTC 3108) were added to 100 g of the dried bitter gourd fruit obtained by drying the bitter gourd fruit, and 1 liter of water was further added and mixed. The resulting mixture was placed in an incubator and incubated at 30° C. for 96 hours to perform lactic acid fermentation. After the lactic acid fermentation was complete, 1 liter of water was further added and heated at 70°C to 85°C for 24 hours. The obtained product was filtered to remove the solvent under vacuum and freeze-dried to obtain an extract of fermented bitter gourd fruit in powder form. The obtained powder was mixed with water and used while stored at -20°C.

Comparative Example 1

1 liter of water was additionally added to 100 g of the dried bitter gourd fruit obtained by drying the bitter gourd fruit and mixed. Heated at 70°C to 85°C for 24 hours. The obtained product was filtered to remove the solvent under vacuum and freeze-dried to obtain a bitter gourd fruit extract in powder form. The obtained powder was mixed with water and used while stored at -20°C.

Experimental Example 1: Analysis of total testosterone content, sex hormone-bonding globulin (SHBG) content, free testosterone content, and prostate specific antigen (PSA) content

12-week-old aged Sprague-Dawley familiy male rats (purchased from DBL, Eumseong, North Chungcheong Province) were prepared, and the rats were subjected to 24°C, 50±10% relative humidity, 10 to 20 times/hour of ventilation, 12 hours. Raised under cycle conditions. Male rats were bred to 50 weeks of age. Male rats were allowed to weigh up to about 560 g. Male rats were divided into two groups. Male rats per group were 40 or 80, respectively.

To one group, the extract of Example 1 was orally administered for 6 weeks, and to the other group, the extract of Comparative Example 1 was orally administered for 6 weeks. In both groups, the daily dose and administration time of the extract were the same. The dose was 20 mg/kg body weight or 40 mg/kg body weight, respectively.

In the above two groups, rats were anesthetized with diethyl ether on the same day and at the same time every week, and 400 to 500 μl of blood was collected from the tail vein. On the last day of the experiment, blood was collected from the heart of the rat. The collected blood was placed in ice and centrifuged at 10,000 x g at 4°C for 10 minutes to collect plasma.

(1) The total testosterone content in blood was measured for the collected plasma using a testosterone measurement kit (Enzo Life Sciences, Montgomery, PA, USA). Specifically, the collected plasma and standard diluent were added to a goat anti-mouse IgG microtiter plate, mixed with testosterone antibody, and incubated at 500 rpm for 1 hour, again at 37 ° C with a substrate solution. Incubated under dark conditions for hours. After that, the stop solution was added and mixed, and absorbance was measured at a wavelength of 405 nm. The obtained absorbance may correspond to the total testosterone content in the blood. The results are shown in Fig. 1 (A). The content of free testosterone was measured using a free testosterone assay kit (Abcam, Cambridge, MA, USA). The results are shown in Fig. 1 (C).

It can be seen that the total testosterone content and free testosterone content were increased when the extract of Example 1 was administered as in FIGS. 1A and 1C , compared to the case where the extract of Comparative Example 1 was administered. .

(2) The content of SHBG in the collected blood was measured using a SHBG analysis kit (Cloud-Clone Corp, Houston, TX, USA). SHBG binds to testosterone to regulate the actual action of testosterone. When SHBG binds to testosterone, the activity of testosterone is neglected.

Plasma samples and standard solutions were added to precoated microplates and incubated in a sealed condition at 37°C for 2 hours. Then, the solution was removed, detection reagent A was added, and incubated at 37° C. in a sealed state for 1 hour. Then, it was washed with a washing buffer, and after removing the solution, detection reagent B was added and incubated at 37° C. for 30 minutes. After washing and removing the solution, the substrate solution was added and incubated for 20 minutes at 37°C under dark conditions. A stop solution was added, and the absorbance at a wavelength of 450 nm was immediately measured. The obtained absorbance may correspond to the SHBG content in the blood. The results are shown in Fig. 1 (B).

The content of prostate-specific antigen (PSA) in the collected blood was measured using a PSA analysis kit (Cusabio, Wuhan, Hubei, China). PSA is a glycoprotein produced only in the prostate and is a tumor marker in the diagnosis and treatment of prostate cancer, and may increase prostatitis, benign prostatic hyperplasia and acute urinary retention.

Plasma samples and standard solutions were added to precoated microplates and reacted at 37°C for 2 hours. Thereafter, the solution was removed, biotin antibody was added, and the reaction was sealed at 37° C. for 2 hours, followed by washing 3 times with wash buffer. Thereafter, the solution was removed, HRP-avidin was added, and the reaction was sealed at 37° C. for 30 minutes, and washed 5 times with a wash buffer. Then, the solution was removed, the substrate solution was added, and the light was blocked at 37° C. for 2 minutes in dark conditions. Then, stop soultion was added and the absorbance at 450 nm was immediately measured. The obtained absorbance may correspond to the PSA content in the blood. The results are shown in Fig. 1 (D).

It can be seen that when the extract of Example 1 was administered as in FIGS. 1B and 1D, the SHBG content and the PSA content were reduced compared to the case where the extract of Comparative Example 1 was administered.

Experimental Example 2: Analysis of body weight, abdominal fat, vastus lateral muscle, and various lipid contents

In the same manner as in Experimental Example 1, 12-week-old male Sprague-Dawley familiy rats were treated with the extract of Example 1 and the extract of Comparative Example 1, respectively. The following were evaluated for each group of rats.

Rats were weighed periodically. The results are shown in Fig. 2 (A).

Cardiac blood was collected from rats, posterior peritoneal fat was removed, and then washed successively with saline. Then, after removing moisture with filter paper, the weight of abdominal fat was measured. The results are shown in Fig. 2 (B).

In the rat, the femoral part was incised and the vastus lateralis was measured. The results are shown in FIG. 2(C).

Total cholesterol, high density cholesterol (HDL), and triglycerides were measured for blood collected from rats using a blood lipid analysis kit (Asan Pharmaceutical Co. Ltd.). The results are shown in (D), (E), (F) of FIG. 2 .

As shown in (A), (B), (C), (D), (E), (F) of Figure 2, when the extract of Example 1 was administered, when the extract of Comparative Example 1 was administered It can be seen that the contrast weight, muscle mass, and HDL increased, while fat, total cholesterol, and triglycerides decreased.

Experimental Example 3: Forced swimming analysis, total sperm, and analysis of the number of motile sperm

In the same manner as in Experimental Example 1, 12-week-old male Sprague-Dawley familiy rats were treated with the extract of Example 1 and the extract of Comparative Example 1, respectively. The following were evaluated for each group of rats.

The plastic water tank (W50 × D40 × H60, cm) was filled with sterilized water to approximately 30 cm, and the temperature of the sterilized water was maintained at 24±2°C using a water bath heater (EHEIM GmbH & Co KG, Deizisau, Germany). . The rats of this group were placed in the plastic water bath tank. When the rat's nose was submerged 5 times for more than 2 seconds below the water level, the rat was considered exhausted, and the time until it was exhausted was measured. The results are shown in Fig. 3 (A).

The left and right epididymis of the rats were extracted, chopped with surgical scissors, and incubated in 4 ml of 37° C. M199 medium containing 0.5% BSA for 10 minutes, and then sperm were collected. The collected sperm was first diluted in M199 medium at 32°C to make it similar to the rat in vivo environment to improve the survival rate. A second diluent was prepared by adding 100 μl of the first diluent to 900 μl of M199 medium. The sperm count was then determined using a hemocytometer by applying 10 μl of the second diluent. Motile sperm was calculated by measuring the percentage of active sperm count. The results are shown in (B) and (C) of FIG. 3 .

As shown in (A), (B), and (C) of FIG. 3 , when the extract of Example 1 was administered, the forced swimming time, total sperm count, and motile sperm were compared to when the extract of Comparative Example 1 was administered. It can be seen that the number has increased.

Experimental Example 4: Expression analysis of testosterone biosynthesis-related genes

The TM3 cell line was purchased from the Cell Line Bank of Korea (Seoul, Korea). A total of 1 x 10 ⁶ TM3 cells were cultured in DMEM/F-12 medium (Gibco-BRL, Grand Island, New York, USA) containing 10% FBS in a 60 mm cell culture dish (SPL Life Science, Pocheon-si, Gyeonggi-do, Korea) at 37°C for 5 minutes. % CO ₂ Incubated in an incubator. After 24 hours, the medium was discarded and the cells were washed once with PBS.

A fresh medium each containing the extracts of Example 1 and Comparative Example 1 was added to each cell culture dish and cultured for an additional 48 hours. To compare differences in relative gene expression levels related to testosterone biosynthesis, RNA was extracted from cells using Trizol Reagent (Gibco-BRL). cDNA was synthesized from RNA extracted with a ThermoScript RT-PCR system (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and analyzed using RT-PCR (Exicycler96 real-time quantitative thermal block) (Bioneer). The primer sequences used for RT-PCR are shown in Table 1:

17,20-lyase forward 5'-CCTGCTGGAAGGTGTAGCTC-3' SEQ ID NO: 1 reverse 5'-CCTGCTGGAAGGTGTAGCTC-3' SEQ ID NO: 2 17β-HSD3 forward 5'-GTTCTCGCAGCACCTTTTC-3' SEQ ID NO: 3 reverse 5'-CAGCTTCCAGTGGTCCTCTC-3' SEQ ID NO: 4 aromatase forward 5'-ACAATAAGATGTATGGAGAGTTCA-3' SEQ ID NO: 5 reverse 5'-GCTTGAGGACTTGCTGATAA-3' SEQ ID NO: 6 5α-reductase forward 5'-GCAAGCCTATTACCTGGTT-3' SEQ ID NO: 7 reverse 5'-AGAAGACACCGACGCTAA-3' SEQ ID NO: 8 GADPH
(internal control) forward 5'-AACTTTGGCATTGTGGAAGG-3' SEQ ID NO: 9 reverse 5'-CACATTGGGGGTAGGAACAC-3' SEQ ID NO: 10

The results are shown in (A), (B), (C) and (D) of FIG. 4 .

As shown in (A), (B), (C), and (D) of FIG. 4 , 17,20-lyase and 17β-HSD3, which are enzymes involved in testosterone biosynthesis, were administered when the extract of Example 1 was administered. It can be seen that when the extract of Comparative Example 1 was administered, the expression was increased. On the other hand, it can be seen that the expression of aromatase and 5α-reductase, which are enzymes related to testosterone degradation, decreased when the extract of Example 1 was administered compared to when the extract of Comparative Example 1 was administered.

Experimental Example 5: Hepatotoxicity test by ALT and AST analysis

In the same manner as in Experimental Example 1, the extracts of Example 1 and Comparative Example 1 were respectively treated with respect to 12-week-old aged Sprague-Dawley familiy male rats. The following were evaluated for each group of rats.

ALT and AST in the blood of rats were measured using a conventional method. The results are shown in Fig. 5 (A), (B). As shown in (A), (B) of Figure 5, the extract of Example 1 had the same level of AST and ALT in plasma compared to the control group not administered with the extract of Example 1, so that the extract of Example 1 had liver toxicity. It can be seen that there is no

Simple modifications or changes of the present invention can be easily carried out by those of ordinary skill in the art, and all such modifications or changes can be considered to be included in the scope of the present invention.

<110> YOON, Young Geol KIM, Hyun Pyo <120> COMPOSITION FOR IMPROVING, RELIEVING OR PREVENTING ANDROPAUSE SYMPTOMS AND FUNCTIONAL FOOD COMPRISING THE SAME <130> 25077 <160> 10 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> 17,20-LYASE FORWARD PRIMER <400> 1 cctgctggaa ggtgtagctc 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> 17,20-LYASE REVERSE PRIMER <400> 2 cctgctggaa ggtgtagctc 20 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> 17BETA-HSD3 FORWARD PRIMER <400> 3 gttctcgcag caccttttc 19 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> 17BETA-HSD3 REVERSE PRIMER <400> 4 cagcttccag tggtcctctc 20 <210> 5 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> AROMATASE FORWARD PRIMER <400> 5 acaataagat gtatggagag ttca 24 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> AROMATASE REVERSE PRIMER <400> 6 gcttgaggac ttgctgataa 20 <210> 7 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> 5ALPHA-REDUCTASE FORWARD PRIMER <400> 7 gcaagcctat tacctggtt 19 <210> 8 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> 5ALPHA-REDUCTASE REVERSE PRIMER <400> 8 agaagacacc gacgctaa 18 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GADPH FORWARD PRIMER <400> 9 aactttggca ttgtggaagg 20 <210> 10 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GADPH REVERSE PRIMER <400> 10 cacatgggg gtaggaacac 20

Claims (5)

A food composition for improving, alleviating, or preventing androgenic syndrome, comprising an extract of fermented bitter melon ( Momordica charantia , bitter melon) as an active ingredient.
According to claim 1, wherein the fermentation is Lactobacillus plantarum ( Lactobacillus plantarum ) The food composition for improving, alleviating or preventing male menopausal syndrome, which is performed by.
A pharmaceutical composition for the treatment, improvement, alleviation or prevention of male menopausal syndrome, comprising an extract of fermented bitter melon ( Momordica charantia , bitter melon) as an active ingredient.
According to claim 3, wherein the fermentation is Lactobacillus plantarum ( Lactobacillus plantarum ) The pharmaceutical composition for the treatment, improvement, alleviation or prevention of male menopausal syndrome, which is performed by.
The functional food containing the food composition of claim 1.

Images